Comparative Safety Assessment of High and Low Doses of Anlotinib in Combination with PD-1 Monoclonal Antibody for Advanced Non-small Cell Lung Cancer Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38430167/
Findings suggest that combining low-dose AN with PD-1 monoclonal antibody therapy is a safer approach in the treatment of advanced NSCLC. These findings advocate for the adoption of a tailored,...
In advanced NSCLC, combining low-dose anlotinib with PD-1 antibody provided similar efficacy but fewer adverse effects and inflammatory responses than high-dose therapy, supporting a safer, patient-centered dosing approach for improved tolerance.
Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41090299/
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) have revolutionized the treatment landscape for Non-Small Cell Lung Cancer (NSCLC). However, resistance invariably curtails their long-term efficacy. This comprehensive review...
This review comprehensively explores mechanisms of EGFR TKI resistance in NSCLC—including on-target, bypass, and phenotypic pathways—and highlights evolving diagnostic and therapeutic strategies, including fourth-generation TKIs, ADCs, and precision combination therapies.
A stage IIIB NSCLC patient had temporary stabilization post-durvalumab recurrence with durvalumab, tremelimumab, cisplatin, and pemetrexed, underscoring the need for standardized post-durvalumab management strategies.
Efficacy of combined immunotherapy and chemotherapy in recurrent non-small cell lung cancer during durvalumab maintenance therapy: A case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41050778/
Concurrent chemoradiotherapy (CCRT) followed by durvalumab consolidation is the standard treatment for patients with locally advanced non-small cell lung cancer (NSCLC) with a good performance status. However, there is currently...
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39761483/
Encouraging and durable antitumor activity was observed with Dato-DXd in this heavily pretreated advanced/metastatic NSCLC population with actionable genomic alterations. The rate of treatment-related grade ≥3 toxicities was comparable with...
Datopotamab deruxtecan showed durable antitumor activity and manageable safety in heavily pretreated advanced NSCLC with actionable mutations, achieving 35.8% response rate and 78.8% disease control.
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40673977/
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These...
EGFR mutations have transformed NSCLC care with TKIs, now used from early to advanced stages. Advances include combination strategies, biomarker-driven selection, and resistance mechanism insights, guiding optimized treatment.